EP Patent

EP1858891A2 — Crystalline forms of ziprasidone mesylate

Assigned to Teva Pharmaceutical Industries Ltd · Expires 2007-11-28 · 18y expired

What this patent protects

Provided are polymorphic forms of ziprasidone mesylate and processes for their preparation.

USPTO Abstract

Provided are polymorphic forms of ziprasidone mesylate and processes for their preparation.

Drugs covered by this patent

Patent Metadata

Patent number
EP1858891A2
Jurisdiction
EP
Classification
—
Expires
2007-11-28
Drug substance claim
No
Drug product claim
No
Assignee
Teva Pharmaceutical Industries Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.